small molecule glp-1 agonist Aleniglipron: An Oral, GLP-1R Fast-Follower from Structure Therapeutics Emerging Trends in the Development
Description
Patients lost to follow-up were managed using the available data up to the point of their last recorded visit
A meta-analysis of studies does show that people who lose more weight (e.g
Expanding Applications: Clinical trials are actively investigating the use of GLP-1 RAs for a wider range of conditions, including addiction, kidney disease, and neurodegenerative disorders, based on their broad physiological effects
The data used in this study was collected on 17 January 2023
glycaemic control) often play a role in determining the best choice
